Goldman Sachs’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-620,135
| Closed | -$533K | – | 5780 |
|
|
2019
Q4 | $533K | Sell |
620,135
-55,564
| -8% | -$42.7K | ﹤0.01% | 4470 |
|
|
2019
Q3 | $379K | Buy |
675,699
+17,387
| +3% | +$9.35K | ﹤0.01% | 4573 |
|
|
2019
Q2 | $342K | Buy |
658,312
+16,744
| +3% | +$8.36K | ﹤0.01% | 4566 |
|
|
2019
Q1 | $289K | Buy |
641,568
+19,320
| +3% | +$9.02K | ﹤0.01% | 4647 |
|
|
2018
Q4 | $299K | Buy |
622,248
+91,503
| +17% | +$45.5K | ﹤0.01% | 4640 |
|
|
2018
Q3 | $281K | Buy |
530,745
+20,608
| +4% | +$11K | ﹤0.01% | 4753 |
|
|
2018
Q2 | $255K | Buy |
510,137
+10,948
| +2% | +$5.1K | ﹤0.01% | 4867 |
|
|
2018
Q1 | $211K | Buy |
499,189
+6,440
| +1% | +$2.59K | ﹤0.01% | 4977 |
|
|
2017
Q4 | $187K | Buy |
492,749
+19,964
| +4% | +$7.57K | ﹤0.01% | 5459 |
|
|
2017
Q3 | $170K | Buy |
472,785
+20,608
| +5% | +$7.63K | ﹤0.01% | 5847 |
|
|
2017
Q2 | $172K | Buy |
452,177
+20,608
| +5% | +$8.41K | ﹤0.01% | 5879 |
|
|
2017
Q1 | $194K | Buy |
431,569
+19,964
| +5% | +$8.77K | ﹤0.01% | 5748 |
|
|
2016
Q4 | $156K | Buy |
411,605
+20,286
| +5% | +$6.87K | ﹤0.01% | 5926 |
|
|
2016
Q3 | $106K | Buy |
391,319
+20,930
| +6% | +$5.3K | ﹤0.01% | 6204 |
|
|
2016
Q2 | $89K | Buy |
370,389
+20,608
| +6% | +$3.54K | ﹤0.01% | 6188 |
|
|
2016
Q1 | $40K | Buy |
349,781
+19,964
| +6% | +$2.16K | ﹤0.01% | 6525 |
|
|
2015
Q4 | $37K | Buy |
329,817
+19,033
| +6% | +$2.69K | ﹤0.01% | 6681 |
|
|
2015
Q3 | $59K | Buy |
310,784
+10,808
| +4% | +$3.68K | ﹤0.01% | 6734 |
|
|
2015
Q2 | $210K | Buy |
299,976
+16,528
| +6% | +$11.4K | ﹤0.01% | 6111 |
|
|
2015
Q1 | $192K | Sell |
283,448
-1,471
| -0.5% | -$1.03K | ﹤0.01% | 6048 |
|
|
2014
Q4 | $225K | Buy |
284,919
+7,173
| +3% | +$4.9K | ﹤0.01% | 6061 |
|
|
2014
Q3 | $129K | Buy |
277,746
+65,735
| +31% | +$31.9K | ﹤0.01% | 6454 |
|
|
2014
Q2 | $106K | Buy |
212,011
+19,064
| +10% | +$9.22K | ﹤0.01% | 6527 |
|
|
2014
Q1 | $60K | Buy |
192,947
+19,110
| +11% | +$7.1K | ﹤0.01% | 6526 |
|
|
2013
Q4 | $59K | Buy |
173,837
+20,818
| +14% | +$25.2K | ﹤0.01% | 6396 |
|
|
2013
Q3 | $309K | Buy |
153,019
+20,712
| +16% | +$39.5K | ﹤0.01% | 5547 |
|
|
2013
Q2 | $251K | Buy |
+132,307
| New | +$232K | ﹤0.01% | 5442 |
|
Goldman Sachs's GCVRZ Position: Q1 2020 in Review
Goldman Sachs sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 620,135 shares — an estimated $533K sold.
Goldman Sachs first reported a position in GCVRZ in Q2 2013 and held it in 27 quarters. The position peaked at $533K in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Goldman Sachs reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 620,135 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $533K.
- Goldman Sachs first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's Sanofi Contingent Value Rights position peaked at $533K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.